Patrick Fortune - PAREXEL International Independent Director

Dr. Patrick J. Fortune, Ph.D., is Independent Director of Parexel International Corporationrationration. is Chairman of the Human Resources Committee and a member of the Audit and Finance Committee and the Compensation Committee. Since September 2014, Dr. Fortune has served as Sector LeaderSenior Advisor, Innovation of Partners Healthcare. From June 2012 to September 2014, he served as Senior General Manager of Innovations at The Cleveland Clinic, an educational medical center. Since September 2001, Dr. Fortune has served as a Partner of Boston Millennia Partners, a VC firm. From September 2001 to June 2005, he served as Executive Chairman of Knowledge Impact Systems, Inc., a software end user training company. From April 1999 to June 2001, he served as President, Chief Operating Officer and a director of New Era of Networks, Inc., an Internet software and services company. From October 1995 to March 1999, Dr. Fortune was Vice President, Information Technology and Chief Information Officer of Monsanto Company, an agricultural, pharmaceutical and food products company. From August 1994 to July 1995, Dr. Fortune was President and Chief Operating Officer, Chief Information Officer and a member of the Board of Directors of Coram Healthcare Corporationrationration, a medical therapy services company. From December 1991 to August 1994, Dr. Fortune was Corporationrationrate Vice President, Information Management at BristolMyers Squibb, a pharmaceutical company. Prior to that, Dr. Fortune was Senior Vice President and General Manager of Packaging Corporationrationration of America, a subsidiary of Tenneco, and held several management positions with Baxter International, Inc., including Corporationrationrate Vice President President, Parenteral Products Division Vice President, Research and Development and Vice President, Information Services. Dr. Fortune also served on the boards of directors of CombinatoRx, Incorporated from 2006 to 2009 and EPIX Pharmaceuticals, Inc. from 2006 to 2008.
Age: 68  Director Since 1996      
781 487-9900

Patrick Fortune Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of 0.05 % which means that it generated profit of $0.05 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of 0.15 % meaning that it created $0.15 on every $100 dollars invested by stockholders.
The company currently holds 671.5 M in liabilities with Debt to Equity (D/E) ratio of 105.8 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. PAREXEL International has Current Ratio of 1.42 which is within standard range for the sector.

Similar Executives

Showing few of many executives


Bruce SachsVertex Pharmaceuticals Incorpor
David GreenwayVertex Pharmaceuticals Incorpor
Theodore SamuelsPerrigo Company Plc
Alfred GilmanRegeneron Pharmaceuticals
Frank DAmelioZoetis
Adriana KaraboutisPerrigo Company Plc
Margaret McGlynnVertex Pharmaceuticals Incorpor
Lloyd CarneyVertex Pharmaceuticals Incorpor
J MoreauDr Reddys Laboratories Ltd
Bruce CarterDr Reddys Laboratories Ltd
Bradley AlfordPerrigo Company Plc
Yingqi XiaOrigin Agritech Limited
Bonnie BasslerRegeneron Pharmaceuticals
Willie ReedZoetis
Gary KunklePerrigo Company Plc
Min TangOrigin Agritech Limited
Anupam PuriDr Reddys Laboratories Ltd
Michael BrownRegeneron Pharmaceuticals
Laurie BrlasPerrigo Company Plc
William DoyleZoetis
Ellen HoffingPerrigo Company Plc

Entity Summary

PAREXEL International Corporationration, a biopharmaceutical services company, offer clinical research, clinical logistics, medical communications, consulting, commercialization, and advanced technology solutions and services for pharmaceutical, biotechnology, and medical device industries worldwide. PAREXEL International Corp (PRXL) is traded on NASDAQ in USA and employs 18,600 people.

PAREXEL International Leadership Team

Michelle Graham, Chief Human Resource Officer, Senior Vice President
Ulf Schneider, Chief Administrative Officer, Senior Vice President
Thomas Senderovitz, Senior Vice President - Clinical Research Services
Dana Callow, Presiding Independent Director
Emma Reeve, Interim CFO, Corporate Vice President Controller
Josef Rickenbach, Founder, Chairman and CEO
Patrick Fortune, Independent Director
Eduard Holdener, Independent Director
Simon Harford, CFO, Senior Vice President
Joshua Schultz, Senior Vice President-Worldwide Head of PAREXEL Access
Gadi Saarony, Senior Vice President - Clinical Research Services
Ellen Zane, Director, Member of Compensation Committee, Member of HR Committee, CEO of Tufts Medical Center and President of Tufts Medical Center
Christian Dreger, Senior Vice President - Parexel Access and Parexel Consulting
Xavier Flinois, President - Perceptive Informatics
Douglas Batt, Sr. VP, General Counsel and Secretary
Sybrand Pretorius, Senior Vice President Chief Scientific Officer
Maykin Ho, Director
Richard Love, Independent Director
Ronald Aldridge, Sr. Director, Investor Relations
Mark Goldberg, President COO
Roland Andersson, Senior Vice President - Clinical Research Services
Christopher Lindop, Independent Director
Ingo Bank, CFO and Sr. VP
David Godwin, Senior Vice President-Global Business

Stock Performance Indicators

Current Sentiment - PRXL

PAREXEL International Investor Sentiment

Most of Macroaxis users are at this time bullish on PAREXEL International Corp. What is your perspective on investing in PAREXEL International Corp? Are you bullish or bearish?
98% Bullish
2% Bearish

Currently Active Assets on Macroaxis

Purchased over 200 shares of
a day ago
Traded for 14.76
Purchased over 50 shares of
a day ago
Traded for 53.37
Purchased few shares of
a day ago
Traded for 270.71
Purchased over 40 shares of
a day ago
Traded for 75.81
Purchased over 20 shares of
a day ago
Traded for 147.08
See also Your Equity Center. Please also try Cryptocurrency Arbitrage module to find pairs of digital assets on multiple exchanges that are traded at a risk free arbitrage.